Afuco™ Anti-Human TNFRSF8 ADCC Therapeutic Antibody (XmAb 2513), ADCC Enhanced
Anti-TNFRSF8 ADCC Enhanced Antibody (XmAb 2513) is an ADCC enhanced antibody produced by our Afuco™ platform. XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It is in Phase I clinical development for the treatment of relapsed Hodgkin lymphoma and T cell lymphomas.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-611CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | TNFRSF8 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |